Type 2 Diabetes Medication Review

被引:33
作者
Sterrett, James J. [1 ]
Bragg, Scott [1 ]
Weart, Charles Wayne [1 ]
机构
[1] South Carolina Coll Pharm, Charleston, SC USA
关键词
Type; 2; diabetes; Systemic review; Medications; Pharmacotherapy; Newer drugs; CARDIOVASCULAR OUTCOMES; GLYCEMIC CONTROL; OPEN-LABEL; FOLLOW-UP; INSULIN GLARGINE; EXENATIDE TWICE; METFORMIN; SAFETY; METAANALYSIS; LIRAGLUTIDE;
D O I
10.1016/j.amjms.2016.01.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Patients with type 2 diabetes and their healthcare providers have a variety of medication options available for treating elevated blood glucose values. These medication choices have expanded drastically over the last 10 years with a large number of glucose lowering medications gaining FDA approval. Methods: Here, we have included an extensive search of the type 2 diabetes literature focusing on articles which impact patient-oriented evidence that maters (POEMs). Results: Choosing the best agent(s) can be challenging and requires weighing the risks and benefits of each particular medication. Tailoring medications to individual patients should be prioritized based on trials with cardiovascular outcome data, potential hemoglobin A1c reduction/goal, serious medication precautions and side-effects, co-morbid medical conditions, and cost. Conclusions: This paper will provide the reader with an overview of the pros and cons for each antiglycemic medication class and specific drugs where appropriate. Data relevant to most patient centered encounters will be provided, including safety, tolerability, efficacy, cost, and simplicity of use.
引用
收藏
页码:342 / 355
页数:14
相关论文
共 82 条
[81]   Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [J].
Zinman, Bernard ;
Wanner, Christoph ;
Lachin, John M. ;
Fitchett, David ;
Bluhmki, Erich ;
Hantel, Stefan ;
Mattheus, Michaela ;
Devins, Theresa ;
Johansen, Odd Erik ;
Woerle, Hans J. ;
Broedl, Uli C. ;
Inzucchi, Silvio E. ;
Aizenberg, D. ;
Ulla, M. ;
Waitman, J. ;
De Loredo, L. ;
Farias, J. ;
Fideleff, H. ;
Lagrutta, M. ;
Maldonado, N. ;
Colombo, H. ;
Ferre Pacora, F. ;
Wasserman, A. ;
Maffei, L. ;
Lehman, R. ;
Selvanayagam, J. ;
d'Emden, M. ;
Fasching, P. ;
Paulweber, B. ;
Toplak, H. ;
Luger, A. ;
Drexel, H. ;
Prager, R. ;
Schnack, C. ;
Schernthaner, G. ;
Fliesser-Goerzer, E. ;
Kaser, S. ;
Scheen, A. ;
Van Gaal, L. ;
Hollanders, G. ;
Kockaerts, Y. ;
Capiau, L. ;
Chachati, A. ;
Persu, A. ;
Hermans, M. ;
Vantroyen, D. ;
Vercammen, C. ;
Van de Borne, P. ;
Mathieu, C. ;
Benhalima, K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22) :2117-2128
[82]   Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes A 1-year, randomized, treat-to-target trial (BEGIN Once Long) [J].
Zinman, Bernard ;
Philis-Tsimikas, Athena ;
Cariou, Bertrand ;
Handelsman, Yehuda ;
Rodbard, Helena W. ;
Johansen, Thue ;
Endahl, Lars ;
Mathieu, Chantal .
DIABETES CARE, 2012, 35 (12) :2464-2471